Lasa Supergenerics Ltd. (LASA) AI Stock Analysis

• Market Cap: ₹585.18M
• Dividend Yield: N/A
• Average Volume (3M): 39.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: -20.40%
• EPS Growth: -59.20%
• Country: IN
• Employees: 77
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -1.25
• Shares Outstanding: 50,101,240
• 10 Day Avg. Volume: 9,122
• 30 Day Avg. Volume: 39,131
• PEG Ratio: 0.19
• Price to Book (P/B): 1.08
• Price to Sales (P/S): 0.63
• P/FCF Ratio: -32.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: ₹10.00 ▲(4.71% Upside)

The overall stock score is primarily impacted by the company's financial distress, characterized by declining revenues and negative cash flows. Technical indicators further reflect a bearish trend, and poor valuation metrics underscore the company's challenges.

Positive Factors

Global Market Reach

Lasa's global market operations provide diversified revenue streams and reduce dependency on a single market, supporting long-term growth.

Strategic Partnerships

Partnerships with large corporations expand Lasa's product portfolio and market reach, fostering innovation and competitive advantage.

R&D Investment

Continuous R&D investment ensures Lasa remains competitive by developing new products, supporting sustained revenue growth and market position.

Negative Factors

Declining Revenues

Persistent revenue decline indicates challenges in market demand or competitive pressures, threatening long-term financial stability.

Negative Cash Flows

Negative cash flows limit Lasa's ability to reinvest in growth opportunities and meet financial obligations, impacting future operations.

Persistent Losses

Ongoing losses reflect operational inefficiencies and financial distress, posing risks to long-term viability and shareholder value.

Lasa Supergenerics Ltd. Business Overview & Revenue Model

Company Description

Lasa Supergenerics Ltd. (LASA) is a leading player in the pharmaceutical and biotechnology sectors, primarily engaged in the manufacturing and marketing of a diverse range of active pharmaceutical ingredients (APIs) and formulations. The company focuses on producing high-quality generics, specialty pharmaceuticals, and veterinary products, catering to both domestic and international markets. LASA is dedicated to innovation and sustainability, utilizing advanced technology to enhance its product offerings and operational efficiency.

How the Company Makes Money

Lasa Supergenerics Ltd. generates revenue through multiple streams, primarily from the sale of its pharmaceutical products, including APIs and finished formulations. The company operates in a global market, exporting its products to various countries, which significantly contributes to its earnings. Additionally, LASA engages in contract manufacturing for other pharmaceutical companies, which provides a consistent revenue source. Strategic partnerships with multinational corporations and collaborations with research institutions also enhance its revenue potential by expanding its product portfolio and market reach. The company invests in research and development to innovate new products, ensuring a competitive edge and sustained growth in revenue.

Lasa Supergenerics Ltd. Financial Statement Overview

Summary

Lasa Supergenerics Ltd. is experiencing financial distress with declining revenues, persistent losses, and negative cash flows. Despite a manageable debt-to-equity ratio, the company's inability to generate profits and positive cash flows poses significant risks.

Income Statement

Lasa Supergenerics Ltd. has faced declining revenues over the past years, with a negative revenue growth rate of approximately -30% from 2021 to 2025. The company's gross profit margin has also deteriorated significantly, indicating shrinking profitability. Furthermore, the net profit margin remains negative, which highlights persistent losses. The EBIT and EBITDA margins show negative trends, further stressing operational inefficiencies.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio, which suggests manageable leverage levels. However, the return on equity has been negative, reflecting the company's inability to generate profits from shareholder equity. The equity ratio remains relatively strong, suggesting a good proportion of assets financed by equity, though the overall financial health is challenged by persistent losses.

Cash Flow

Lasa's cash flow situation is concerning, with a negative free cash flow growth rate and negative operating cash flow in the latest period. The operating cash flow to net income ratio is negative, indicating cash flow issues in relation to net income. While the free cash flow to net income ratio is also negative, it highlights cash flow challenges that could impact future operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.32B	1.42B	1.04B	1.30B	1.37B	2.02B
Gross Profit	318.16M	362.61M	286.95M	-111.88M	427.84M	886.86M
EBITDA	-251.84M	-43.91M	-64.66M	-246.85M	84.12M	469.92M
Net Income	-331.45M	-147.57M	-217.31M	-386.21M	-53.31M	227.78M
Balance Sheet
Total Assets	0.00	1.02B	1.51B	1.64B	2.09B	2.08B
Cash, Cash Equivalents and Short-Term Investments	7.90M	7.90M	14.96M	21.78M	172.17M	44.00M
Total Debt	0.00	21.27M	220.76M	217.70M	201.71M	194.63M
Total Liabilities	-837.13M	178.19M	541.92M	455.69M	512.87M	489.43M
Stockholders Equity	837.13M	837.13M	966.76M	1.18B	1.58B	1.59B
Cash Flow
Free Cash Flow	0.00	-28.24M	21.39M	-173.00M	92.12M	347.24M
Operating Cash Flow	0.00	-28.24M	21.39M	-173.00M	92.12M	413.10M
Investing Cash Flow	0.00	81.52M	-3.98M	111.95M	-29.12M	-35.97M
Financing Cash Flow	0.00	-56.62M	-19.32M	-41.61M	-403.00K	-364.43M

Lasa Supergenerics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LASA, the sentiment is Negative. The current price of 9.55 is below the 20-day moving average (MA) of 10.73, below the 50-day MA of 11.26, and below the 200-day MA of 14.38, indicating a bearish trend. The MACD of -0.39 indicates Positive momentum. The RSI at 36.37 is Neutral, neither overbought nor oversold. The STOCH value of 21.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LASA.

Lasa Supergenerics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BALAXI	62 Neutral	₹419.58M	10.47	―	―	―	―
BALPHARMA	58 Neutral	₹1.30B	15.34	―	1.60%	-9.07%	5.36%
BIOFILCHEM	55 Neutral	₹644.44M	23.02	―	―	36.76%	433.63%
INDSWFTLTD	53 Neutral	―	―	―	―	2.59%	1891.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AAREYDRUGS	46 Neutral	₹2.78B	66.68	―	―	-17.47%	-50.07%
LASA	43 Neutral	₹585.18M	-1.77	―	―	-20.40%	-59.20%

Lasa Supergenerics Ltd. Corporate Events

Lasa Supergenerics Reinforces Compliance with SDD Certification

Lasa Supergenerics Ltd. has issued a compliance certificate for the quarter ending September 30, 2025, in line with the Securities and Exchange Board of India’s regulations on insider trading. The certificate confirms that the company has a robust Structured Digital Database (SDD) system in place, ensuring secure access and accurate tracking of unpublished price-sensitive information (UPSI). This compliance reinforces Lasa Supergenerics’ commitment to regulatory standards and enhances its credibility in the pharmaceutical industry, potentially benefiting stakeholders by ensuring transparency and data integrity.

Lasa Supergenerics Announces Key Decisions from Board Meeting

Lasa Supergenerics Ltd. held a board meeting on September 5, 2025, where several key decisions were made. The board approved the notice for the company’s 10th Annual General Meeting, scheduled for September 30, 2025, to be conducted via video conferencing. Additionally, the board approved the Director’s Report and related documents for the financial year ending March 31, 2025, appointed Shravan A. Gupta & Associates as the scrutinizer for the AGM, and re-appointed Mr. Omkar Herlekar as a director. The company also announced the closure of its Register of Members and Share Transfer Books from September 23 to September 29, 2025.